Petit, A M <br/><br/>
Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.  [electronic resource] 

 -  The American journal of pathology  Dec 1997 
 - 1523-30 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0002-9440 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Animals<br/>Antibodies, Monoclonal--pharmacology<br/>Breast Neoplasms--drug therapy<br/>Carcinoma, Squamous Cell--drug therapy<br/>Dose-Response Relationship, Drug<br/>Down-Regulation--drug effects<br/>Endothelial Growth Factors--metabolism<br/>Epidermal Growth Factor--immunology<br/>Gene Expression Regulation, Neoplastic<br/>Humans<br/>Immunoenzyme Techniques<br/>Lymphokines--metabolism<br/>Mice<br/>Mice, Nude<br/>Neoplasm Transplantation<br/>Neovascularization, Pathologic--drug therapy<br/>Neutralization Tests<br/>Receptor, ErbB-2--immunology<br/>Signal Transduction--physiology<br/>Tumor Cells, Cultured<br/>Vascular Endothelial Growth Factor A<br/>Vascular Endothelial Growth Factors